Nakanoshima Qross Global Life Sciences Cluster vol.4
Nakanoshima Qross Global Life Sciences Cluster vol.4
*Japanese follows English
A Special Program Connecting Global Startups, Investment Communities, and Business Opportunities
Building on the growing interest and opportunities for exchange generated by Expo 2025 Osaka, Kansai, this program aims to transform these connections from a one-time opportunity into continuous collaboration.
Through Nakanoshima Qross, we seek to foster an international life science innovation ecosystem and investment community that connects startups, investors, corporations, research institutions, and global innovation hubs.
The program will feature two events. In addition to introducing activities and initiatives by overseas life science clusters, VCs, and CVCs, promising Japanese startups will deliver pitches designed to facilitate new business matching and international collaboration among investors, corporations, and startups.
Who Should Attend
Life science and healthcare startups
VCs, CVCs, investors, and corporate investors
Companies in pharmaceuticals, medical devices, diagnostics, regenerative medicine, biomanufacturing, and digital health
Universities, research institutions, and healthcare organizations
Overseas life science clusters, accelerators, and support organizations
Companies and organizations interested in collaboration with startups, investment, joint research, business development, and international expansion
Timeline
6:00 PM : Opening＆Presentation on the Nakanoshima Qross Global Life Sciences Cluster Project
Ayano Kagami/Director of CIC Tokyo
6:05 PM : Presentation on the Nakanoshima Cross
Jun Miyagawa:MIRACLE SCIENCE INNOVATION,INC. President & CEO
6:10 PM : Presentation on Overseas Life Sciences Business and Investment Trends
Alloy Therapeutics Alloy Therapeutics Alexander Titus, Ph.D.
Alexander Titus, Ph.D., is an AI and biotechnology executive focused on building the systems required to translate scientific capability into real-world impact. He works at the intersection of technology, national security, and the life sciences, with a career spanning the private sector, government, and academia.
Titus currently leads the Vigilance Division at Alloy Therapeutics, where he is building new approaches to ensuring that critical capabilities, countermeasures, and capital are available when they are needed most. In addition, he serves as a Commissioner on the National Security Commission on Emerging Biotechnology.
He is the founder of In Vivo Group and The Connected Ideas Project, where he writes and advises on the co-evolution of technology, policy, and society. Across his career, he has also held AI research fellowships with Amazon, In-Q-Tel, and within the U.S. Intelligence Community. Titus holds a Ph.D. in Quantitative Biomedical Sciences from Dartmouth College and dual undergraduate degrees in biochemistry and biology from the University of Puget Sound.
6:40 PM : Pitch
PurinoScience is a pre-incorporation drug discovery venture developing a new therapeutic approach based on xanthine oxidoreductase (XOR) inhibition and purine salvage. Our core hypothesis is that XOR inhibition can preserve purines for salvage and support the recovery of lost brain and muscle function. We are starting with Down syndrome as a focused human setting in which to test this biology. Our strategy is to first learn from real-world human exposure to existing XOR inhibitors, establish Human Proof of Biology using pathway biomarkers and functional outcomes, and then use those insights to develop a proprietary next-generation XOR inhibitor. While Down syndrome is our first indication, our long-term ambition is to expand this biology into larger areas including neurological disease, muscle disorders, sarcopenia, and age-related functional decline. PurinoScience aims to combine human learning, translational biology, and proprietary chemistry to create differentiated medicines for functional recovery.
Our core technology Stealth RNA Vector (SRV) is an ideal tool for reprogramming human cells with exogenous factors. We plan to launch new SRV vector for generating clinical-grade human iPSC in 2027.
Calling all Japan-based startups! We are now accepting applications from startups interested in speaking at the event.：here
7:10 PM : Closing Remarks〜Networking
7:30 PM : Close
Overview
Organizer : Osaka Prefecture
Program Office : Organization of Future Medicine
Operational Partner : CIC Japan Innovation Services G.K.
Date & Time : Tuesday, October 6, 2026, 18:00–19:30 JST
Format : Onsite at CIC Tokyo, Online
Language : English (Some announcements may be provided in Japanese.)
========
Nakanoshima Qross Global Life Sciences Cluster
-NQ Global Life Science Startup & Investment Connect-
― 海外スタートアップ、投資コミュニティ、ビジネスマッチングをつなぐ特別プログラム ―
2025年大阪・関西万博を契機に高まった国内外からの関心や交流の機会を、一過性のものではなく継続的な共創へと発展させることを目指し、Nakanoshima Qrossを核とした国際的なライフサイエンス・イノベーションエコシステムおよび投資コミュニティの形成を推進します。
当日は、２つのイベントを開催します。海外のライフサイエンス・クラスターやVC・CVCによる活動紹介に加え、国内有望スタートアップによるピッチを実施し、投資家・事業会社・スタートアップをつなぐ新たなビジネスマッチングと国際連携の創出を促進します。
このような方にオススメ
ライフサイエンス・ヘルスケア領域のスタートアップ
VC、CVC、事業会社、投資家
製薬、医療機器、診断、再生医療、バイオ製造、デジタルヘルス関連企業
大学、研究機関、医療機関
海外クラスター、アクセラレーター、支援機関
スタートアップとの協業、投資、共同研究、事業開発、海外展開に関心のある企業・団体
タイムライン
6:00 PM : 開会及び大阪府/中之島クロスグローバルライフサイエンスクラスター事業についての説明
加々美綾乃 氏 / Director of CIC Tokyo
6:05 PM : 大阪府/中之島クロスについてのご説明
宮川 潤 氏 一般財団法人 未来医療推進機構 理事長補佐 MIRACLE SCIENCE INNOVATION 株式会社 代表取締役CEO
6:10 PM : 海外のライフサイエンスビジネス・投資動向
Alloy Therapeutics Alexander Titus, Ph.D.
Alexander Titus, Ph.D., is an AI and biotechnology executive focused on building the systems required to translate scientific capability into real-world impact. He works at the intersection of technology, national security, and the life sciences, with a career spanning the private sector, government, and academia.
Titus currently leads the Vigilance Division at Alloy Therapeutics, where he is building new approaches to ensuring that critical capabilities, countermeasures, and capital are available when they are needed most. In addition, he serves as a Commissioner on the National Security Commission on Emerging Biotechnology.
He is the founder of In Vivo Group and The Connected Ideas Project, where he writes and advises on the co-evolution of technology, policy, and society. Across his career, he has also held AI research fellowships with Amazon, In-Q-Tel, and within the U.S. Intelligence Community. Titus holds a Ph.D. in Quantitative Biomedical Sciences from Dartmouth College and dual undergraduate degrees in biochemistry and biology from the University of Puget Sound.
6:40 PM : スタートアップによるピッチ：創薬分野
PurinoScienceは、XOR阻害とプリンサルベージを活用し、失われた脳・筋機能の回復を目指す創薬スタートアップ(創業前)です。ダウン症を最初のHuman Proof of Biologyの対象とし、既存XOR阻害薬によるHuman Learningを活用しながら、新規独自XOR阻害薬の開発を進めます。将来的には神経疾患、筋疾患、サルコペニア、加齢に伴う機能低下への展開を目指します。
ヒト細胞に効率よく遺伝子を導入し安定に発現できる純国産技術「ステルス型RNAベクター（SRV）」を使った再生医療技術の実用化を進めています。SRVは発がん性等の副作用が無く、遺伝子を使った細胞リプログラミングや細胞若返りに最適な技術です。2020年には研究用SRV-iPSCベクターの発売を開始し、2027年からは臨床グレードiPSC製造用新型SRV-iPSCの販売を予定しています。
登壇を希望するスタートアップを募集しています！申し込みはこちら
7:10 PM : 閉会挨拶 〜ネットワーキング
7:30 PM : 閉場
開催概要
■主催：大阪府
■運営事務局：一般財団法人未来医療推進機構
■運営協力：CIC Japan Innovation Services 合同会社
■日時：2026/10/６（火）18:00-19:30
■形態：現地（CIC Tokyo）及びオンライン
■言語 : 英語（一部、日本語での案内を含みます。）
VC・CVCのコミュニティ参加者を募集中です！